Skip to content

Advertisement

Articles

Page 1 of 14

  1. Content type: Research

    There are currently no approved treatments for the prodromal stage of Alzheimer’s disease (AD). Approved symptomatic treatments for mild-to-moderate AD include acetylcholinesterase inhibitors and memantine, bu...

    Authors: Lutz Frölich, Glen Wunderlich, Claus Thamer, Michael Roehrle, Miguel Garcia Jr and Bruno Dubois

    Citation: Alzheimer's Research & Therapy 2019 11:18

    Published on:

  2. Content type: Research

    Autosomal dominant Alzheimer’s disease (ADAD) is distinguished from late-onset AD by early striatal amyloid-β deposition. To determine whether striatal Pittsburgh compound B (PiB)-PET measurements of amyloid-β...

    Authors: Bernard J. Hanseeuw, Francisco Lopera, Reisa A. Sperling, Daniel J. Norton, Edmarie Guzman-Velez, Ana Baena, Enmanuelle Pardilla-Delgado, Aaron P. Schultz, Jennifer Gatchel, David Jin, Kewei Chen, Eric M. Reiman, Keith A. Johnson and Yakeel T. Quiroz

    Citation: Alzheimer's Research & Therapy 2019 11:17

    Published on:

  3. Content type: Research

    Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer’s disease (LOAD). Amongst these, a polymorphism in phospholipase C-...

    Authors: Lorenza Magno, Christian B. Lessard, Marta Martins, Verena Lang, Pedro Cruz, Yasmine Asi, Matilda Katan, Jamie Bilsland, Tammaryn Lashley, Paramita Chakrabarty, Todd E. Golde and Paul J. Whiting

    Citation: Alzheimer's Research & Therapy 2019 11:16

    Published on:

  4. Content type: Research

    Current methods of amyloid PET interpretation based on the binary classification of global amyloid signal fail to identify early phases of amyloid deposition. A recent analysis of 18F-florbetapir PET data from...

    Authors: Fatemah A. Sakr, Michel J. Grothe, Enrica Cavedo, Irina Jelistratova, Marie-Odile Habert, Martin Dyrba, Gabriel Gonzalez-Escamilla, Hugo Bertin, Maxime Locatelli, Stephane Lehericy, Stefan Teipel, Bruno Dubois and Harald Hampel

    Citation: Alzheimer's Research & Therapy 2019 11:15

    Published on:

  5. Content type: Research

    A decline in instrumental activities of daily living (IADL) correlates with the progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia and has been associated with frontal and pa...

    Authors: Omar A. Halawa, Jennifer R. Gatchel, Rebecca E. Amariglio, Dorene M. Rentz, Reisa A. Sperling, Keith A. Johnson and Gad A. Marshall

    Citation: Alzheimer's Research & Therapy 2019 11:14

    Published on:

  6. Content type: Research

    The tau positron emission tomography (PET) ligand 18F-flortaucipir binds to paired helical filaments of tau in aging and Alzheimer’s disease (AD), but its utility in detecting tau aggregates in frontotemporal dem...

    Authors: Richard M. Tsai, Alexandre Bejanin, Orit Lesman-Segev, Renaud LaJoie, Adrienne Visani, Viktoriya Bourakova, James P. O’Neil, Mustafa Janabi, Suzanne Baker, Suzee E. Lee, David C. Perry, Lynn Bajorek, Anna Karydas, Salvatore Spina, Lea T. Grinberg, William W. Seeley…

    Citation: Alzheimer's Research & Therapy 2019 11:13

    Published on:

  7. Content type: Research

    White matter hyperintensities (WMH) of presumed vascular origin have been associated with an increased risk of Alzheimer’s disease (AD). This study aims to describe the patterns of WMH associated with dementia...

    Authors: Gemma Salvadó, Anna Brugulat-Serrat, Carole H. Sudre, Oriol Grau-Rivera, Marc Suárez-Calvet, Carles Falcon, Karine Fauria, M. Jorge Cardoso, Frederik Barkhof, José Luis Molinuevo and Juan Domingo Gispert

    Citation: Alzheimer's Research & Therapy 2019 11:12

    Published on:

  8. Content type: Research

    We developed multifactorial models for predicting incident dementia and brain pathology in the oldest old using the Vantaa 85+ cohort.

    Authors: Anette Hall, Timo Pekkala, Tuomo Polvikoski, Mark van Gils, Miia Kivipelto, Jyrki Lötjönen, Jussi Mattila, Mia Kero, Liisa Myllykangas, Mira Mäkelä, Minna Oinas, Anders Paetau, Hilkka Soininen, Maarit Tanskanen and Alina Solomon

    Citation: Alzheimer's Research & Therapy 2019 11:11

    Published on:

  9. Content type: Research

    Although amnestic mild cognitive impairment (aMCI) is generally considered to be a prodromal stage of Alzheimer’s disease, patients with aMCI show heterogeneous patterns of progression. Moreover, there are few...

    Authors: Yeo Jin Kim, Seong-Kyoung Cho, Hee Jin Kim, Jin San Lee, Juyoun Lee, Young Kyoung Jang, Jacob W. Vogel, Duk L. Na, Changsoo Kim and Sang Won Seo

    Citation: Alzheimer's Research & Therapy 2019 11:10

    Published on:

  10. Content type: Research

    Complex visual hallucinations are common in Lewy body dementia (LBD) and can cause significant patient and caregiver distress. Current treatments are primarily pharmacological in nature and have limited effica...

    Authors: Greg J. Elder, Sean J. Colloby, Michael J. Firbank, Ian G. McKeith and John-Paul Taylor

    Citation: Alzheimer's Research & Therapy 2019 11:9

    Published on:

  11. Content type: Research

    Subjective cognitive decline (SCD) in cognitively unimpaired older individuals has been recognized as an early clinical at-risk state for Alzheimer’s disease (AD) dementia and as a target population for future...

    Authors: Steffen Wolfsgruber, José Luis Molinuevo, Michael Wagner, Charlotte E. Teunissen, Lorena Rami, Nina Coll-Padrós, Femke H. Bouwman, Rosalinde E. R. Slot, Linda M. P. Wesselman, Oliver Peters, Katja Luther, Katharina Buerger, Josef Priller, Christoph Laske, Stefan Teipel, Annika Spottke…

    Citation: Alzheimer's Research & Therapy 2019 11:8

    Published on:

  12. Content type: Research

    Alzheimer’s disease (AD) pathology begins several years before the clinical onset. The long preclinical phase is composed of three stages according to the 2011National Institute on Aging and Alzheimer’s Associ...

    Authors: Lucilla Parnetti, Elena Chipi, Nicola Salvadori, Katia D’Andrea and Paolo Eusebi

    Citation: Alzheimer's Research & Therapy 2019 11:7

    Published on:

  13. Content type: Research

    The annual incidence of traumatic brain injury (TBI) in the United States is over 2.5 million, with approximately 3–5 million people living with chronic sequelae. Compared with moderate-severe TBI, the long-te...

    Authors: Wai Hang Cheng, Kris M. Martens, Asma Bashir, Honor Cheung, Sophie Stukas, Ebrima Gibbs, Dhananjay R. Namjoshi, Emily B. Button, Anna Wilkinson, Carlos J. Barron, Neil R. Cashman, Peter A. Cripton and Cheryl L. Wellington

    Citation: Alzheimer's Research & Therapy 2019 11:6

    Published on:

  14. Content type: Research

    Alzheimer’s disease (AD) is the most common cause of dementia in the elderly and the sixth leading cause of death in the United States. AD is mainly considered a complex disorder with polygenic inheritance. De...

    Authors: Alireza Nazarian, Anatoliy I. Yashin and Alexander M. Kulminski

    Citation: Alzheimer's Research & Therapy 2019 11:5

    Published on:

  15. Content type: Research

    Impairment in instrumental activities of daily living (IADL) may occur in the earliest stages of mild cognitive impairment (MCI). However, there are few reliable measures of IADL in MCI or that have a sufficie...

    Authors: Gad A. Marshall, Sarah L. Aghjayan, Maria Dekhtyar, Joseph J. Locascio, Kamal Jethwani, Rebecca E. Amariglio, Sara J. Czaja, David A. Loewenstein, Keith A. Johnson, Reisa A. Sperling and Dorene M. Rentz

    Citation: Alzheimer's Research & Therapy 2019 11:4

    Published on:

  16. Content type: Research

    Exercise is often proposed as a non-pharmacological intervention to delay cognitive decline in people with dementia, but evidence remains inconclusive. Previous studies suggest that combining physical exercise...

    Authors: Esther G. A. Karssemeijer, Justine A. Aaronson, Willem J. R. Bossers, Rogier Donders, Marcel G. M. Olde Rikkert and Roy P. C. Kessels

    Citation: Alzheimer's Research & Therapy 2019 11:3

    Published on:

  17. Content type: Research

    The previously described and validated Erlangen Score (ES) algorithm enables interpretation of the cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), ordering them on an ordinal scale: from neur...

    Authors: Inês Baldeiras, Isabel Santana, Maria João Leitão, Daniela Vieira, Diana Duro, Barbara Mroczko, Johannes Kornhuber and Piotr Lewczuk

    Citation: Alzheimer's Research & Therapy 2019 11:2

    Published on:

  18. Content type: Review

    Alcohol use has been identified as a risk factor for dementia and cognitive decline. However, some patterns of drinking have been associated with beneficial effects.

    Authors: Jürgen Rehm, Omer S. M. Hasan, Sandra E. Black, Kevin D. Shield and Michaël Schwarzinger

    Citation: Alzheimer's Research & Therapy 2019 11:1

    Published on:

  19. Content type: Research

    Cholinesterase inhibitors and memantine have been approved for management of Alzheimer’s disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. ...

    Authors: Kai-Xin Dou, Meng-Shan Tan, Chen-Chen Tan, Xi-Peng Cao, Xiao-He Hou, Qi-Hao Guo, Lan Tan, Vincent Mok and Jin-Tai Yu

    Citation: Alzheimer's Research & Therapy 2018 10:126

    Published on:

  21. Content type: Research

    Trimethylamine N-oxide (TMAO), a small molecule produced by the metaorganismal metabolism of dietary choline, has been implicated in human disease pathogenesis, including known risk factors for Alzheimer’s diseas...

    Authors: Nicholas M. Vogt, Kymberleigh A. Romano, Burcu F. Darst, Corinne D. Engelman, Sterling C. Johnson, Cynthia M. Carlsson, Sanjay Asthana, Kaj Blennow, Henrik Zetterberg, Barbara B. Bendlin and Federico E. Rey

    Citation: Alzheimer's Research & Therapy 2018 10:124

    Published on:

  22. Content type: Research

    Subjective cognitive decline (SCD) consists of self-perceived decline in cognition over time. The occurrence of specific additional features in SCD (so-called SCDplus) confers a higher risk of future cognitive...

    Authors: Gonzalo Sánchez-Benavides, Oriol Grau-Rivera, Marc Suárez-Calvet, Carolina Minguillon, Raffaele Cacciaglia, Nina Gramunt, Carles Falcon, Juan Domingo Gispert and José Luis Molinuevo

    Citation: Alzheimer's Research & Therapy 2018 10:123

    Published on:

  24. Content type: Research

    The quantification of amyloid-beta (Aβ) peptides in blood plasma as potential biomarkers of Alzheimer’s disease (AD) is hampered by very low Aβ concentrations and the presence of matrix components that may int...

    Authors: Hedieh Shahpasand-Kroner, Hans-W. Klafki, Chris Bauer, Johannes Schuchhardt, Melanie Hüttenrauch, Martina Stazi, Caroline Bouter, Oliver Wirths, Jonathan Vogelgsang and Jens Wiltfang

    Citation: Alzheimer's Research & Therapy 2018 10:121

    Published on:

  25. Content type: Correction

    Upon publication of this article [1], it was brought to our attention that one of the 303 participants in the normative study should have been deleted from the database.

    Authors: Morris Freedman, Larry Leach, M. Carmela Tartaglia, Kathryn A. Stokes, Yael Goldberg, Robyn Spring, Nima Nourhaghighi, Tom Gee, Stephen C. Strother, Mohammad O. Alhaj, Michael Borrie, Sultan Darvesh, Alita Fernandez, Corinne E. Fischer, Jennifer Fogarty, Barry D. Greenberg…

    Citation: Alzheimer's Research & Therapy 2018 10:120

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2018 10:65

  26. Content type: Research

    Peripheral biomarkers that identify individuals at risk of developing Alzheimer’s disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials of disea...

    Authors: Itziar de Rojas, J. Romero, O. Rodríguez-Gomez, P. Pesini, A. Sanabria, A. Pérez-Cordon, C. Abdelnour, I. Hernández, M. Rosende-Roca, A. Mauleón, L. Vargas, M. Alegret, A. Espinosa, G. Ortega, S. Gil, M. Guitart…

    Citation: Alzheimer's Research & Therapy 2018 10:119

    Published on:

  27. Content type: Research

    Amyloid-β 1–42 (Aβ1–42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer’s disease (AD). Reduced levels of Aβ1–42 are indicative of AD, but significant variation in the absolute con...

    Authors: Stephen P. Schauer, William R. Mylott Jr, Moucun Yuan, Rand G. Jenkins, W. Rodney Mathews, Lee A. Honigberg and Kristin R. Wildsmith

    Citation: Alzheimer's Research & Therapy 2018 10:118

    Published on:

  28. Content type: Research

    Anti-amyloid β (Aβ) immunotherapy represents a major area of drug development for Alzheimer’s disease (AD). However, Aβ peptide adopts multiple conformations and the pathological forms to be specifically targe...

    Authors: Laurent Pradier, Véronique Blanchard-Brégeon, Andrees Bohme, Thomas Debeir, Jean Menager, Patrick Benoit, Pascal Barneoud, Véronique Taupin, Philippe Bertrand, Philippe Dugay, Béatrice Cameron, Yi Shi, Souad Naimi, Marc Duchesne, Marie Gagnaire, Tim Weeden…

    Citation: Alzheimer's Research & Therapy 2018 10:117

    Published on:

  29. Content type: Research

    Globalization of clinical trials has important consequences for trial planning and interpretation. This study investigated heterogeneity in patient characteristics and outcomes among world regions in the globa...

    Authors: Jeffrey L. Cummings, Alireza Atri, Clive Ballard, Neli Boneva, Lutz Frölich, José Luis Molinuevo, Lars Lau Raket and Pierre N. Tariot

    Citation: Alzheimer's Research & Therapy 2018 10:116

    Published on:

  30. Content type: Research

    Alzheimer’s disease (AD) is the most well-known and most common type of age-related dementia. Amyloid deposition and hyperphosphorylation of tau protein are both pathological hallmarks of AD. Using a triple-tr...

    Authors: Roger N. Rosenberg, Min Fu and Doris Lambracht-Washington

    Citation: Alzheimer's Research & Therapy 2018 10:115

    Published on:

  31. Content type: Research

    Low haemoglobin is highly prevalent among the elderly and has been associated with dementia. However, the mechanisms underlying this association with cognitive dysfunction, either through cerebrovascular disea...

    Authors: Bryce Tan, Narayanaswamy Venketasubramanian, Henri Vrooman, Ching-Yu Cheng, Tien Yin Wong, Christopher Chen and Saima Hilal

    Citation: Alzheimer's Research & Therapy 2018 10:114

    Published on:

  32. Content type: Research

    Biomarkers that can track disease onset and progression in autosomal dominant Alzheimer’s disease (ADAD) are needed. We investigate whether serum neurofilament light (NfL) concentration is associated with clin...

    Authors: Raquel Sánchez-Valle, Amanda Heslegrave, Martha S. Foiani, Beatriz Bosch, Anna Antonell, Mircea Balasa, Albert Lladó, Henrik Zetterberg and Nick C. Fox

    Citation: Alzheimer's Research & Therapy 2018 10:113

    Published on:

  33. Content type: Research

    In Alzheimer’s disease (AD), pathological changes may arise up to 20 years before the onset of dementia. This pre-dementia window provides a unique opportunity for secondary prevention. However, exposing non-d...

    Authors: Mara ten Kate, Silvia Ingala, Adam J. Schwarz, Nick C. Fox, Gaël Chételat, Bart N. M. van Berckel, Michael Ewers, Christopher Foley, Juan Domingo Gispert, Derek Hill, Michael C. Irizarry, Adriaan A. Lammertsma, José Luis Molinuevo, Craig Ritchie, Philip Scheltens, Mark E. Schmidt…

    Citation: Alzheimer's Research & Therapy 2018 10:112

    Published on:

  34. Content type: Research

    Most previous studies on dementia and injuries have focused on a particular type of injury, and few studies have investigated overall injury in people with dementia. In this study, we investigated the risk fac...

    Authors: Ruey Chen, Wu-Chien Chien, Ching-Chiu Kao, Chi-Hsiang Chung, Doresses Liu, Huei-Ling Chiu and Kuei-Ru Chou

    Citation: Alzheimer's Research & Therapy 2018 10:111

    Published on:

  35. Content type: Research

    Variability in biological parameters has been reported to be associated with adverse health outcomes. We aimed to investigate the composite effect of the visit-to-visit variability in blood pressure, glucose, ...

    Authors: Seung-Hwan Lee, Kyungdo Han, Hanna Cho, Yong-Moon Park, Hyuk-Sang Kwon, Gunseog Kang, Kun-Ho Yoon and Mee Kyoung Kim

    Citation: Alzheimer's Research & Therapy 2018 10:110

    Published on:

  36. Content type: Research

    Cerebrovascular pathology, quantified by white matter lesions (WML), is known to affect cognition in aging, and is associated with an increased risk of dementia. The present study aimed to investigate whether ...

    Authors: Gloria Benson, Andrea Hildebrandt, Catharina Lange, Claudia Schwarz, Theresa Köbe, Werner Sommer, Agnes Flöel and Miranka Wirth

    Citation: Alzheimer's Research & Therapy 2018 10:109

    Published on:

  37. Content type: Research

    Neurofibrillary pathology composed of tau protein is closely correlated with severity and phenotype of cognitive impairment in patients with Alzheimer’s disease and non-Alzheimer’s tauopathies. Targeting patho...

    Authors: Petr Novak, Reinhold Schmidt, Eva Kontsekova, Branislav Kovacech, Tomas Smolek, Stanislav Katina, Lubica Fialova, Michal Prcina, Vojtech Parrak, Peter Dal-Bianco, Martin Brunner, Wolfgang Staffen, Michael Rainer, Matej Ondrus, Stefan Ropele, Miroslav Smisek…

    Citation: Alzheimer's Research & Therapy 2018 10:108

    Published on:

  38. Content type: Research

    PQ912 is an inhibitor of the glutaminyl cyclase enzyme that plays a central role in the formation of synaptotoxic pyroglutamate-A-beta oligomers. We report on the first clinical study with PQ912 in subjects wi...

    Authors: Philip Scheltens, Merja Hallikainen, Timo Grimmer, Thomas Duning, Alida A Gouw, Charlotte E Teunissen, Alle Meije Wink, Paul Maruff, John Harrison, Caroline M van Baal, Suzanne Bruins, Inge Lues and Niels D Prins

    Citation: Alzheimer's Research & Therapy 2018 10:107

    Published on:

  39. Content type: Research

    The typical familial form of Alzheimer’s disease (FAD) accounts for about 5% of total Alzheimer’s disease (AD) cases. Presenilins (PSEN1 and PSEN2) and amyloid-β (A4) precursor protein (APP) genes carry all repor...

    Authors: Lara Paracchini, Luca Beltrame, Lucia Boeri, Federica Fusco, Paolo Caffarra, Sergio Marchini, Diego Albani and Gianluigi Forloni

    Citation: Alzheimer's Research & Therapy 2018 10:106

    Published on:

  40. Content type: Research

    Translational research in Alzheimer’s disease (AD) pathology provides evidence that accumulation of amyloid-β and hyperphosphorylated tau, neuropathological hallmarks of AD, is associated with complex disturba...

    Authors: Milan Stoiljkovic, Craig Kelley, Tamas L. Horvath and Mihály Hajós

    Citation: Alzheimer's Research & Therapy 2018 10:105

    Published on:

  42. Content type: Research

    The protective effect of education has been well established in Alzheimer’s disease, whereas its role in patients with isolated cerebrovascular diseases remains unclear. We examined the correlation of educatio...

    Authors: Na-Yeon Jung, Hanna Cho, Yeo Jin Kim, Hee Jin Kim, Jong Min Lee, Seongbeom Park, Sung Tae Kim, Eun-Joo Kim, Jae Seung Kim, Seung Hwan Moon, Jae-Hong Lee, Michael Ewers, Duk L Na and Sang Won Seo

    Citation: Alzheimer's Research & Therapy 2018 10:103

    Published on:

  43. Content type: Research

    There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been associated with symptomatic improvements across animal models and sev...

    Authors: Elizabeth Finger, Scott Berry, Jeffrey Cummings, Kristy Coleman, Robin Hsiung, Howard H. Feldman and Adam Boxer

    Citation: Alzheimer's Research & Therapy 2018 10:102

    Published on:

  45. Content type: Research

    With the shift of research focus towards the pre-dementia stage of Alzheimer’s disease (AD), there is an urgent need for reliable, non-invasive biomarkers to predict amyloid pathology. The aim of this study wa...

    Authors: Mara ten Kate, Alberto Redolfi, Enrico Peira, Isabelle Bos, Stephanie J. Vos, Rik Vandenberghe, Silvy Gabel, Jolien Schaeverbeke, Philip Scheltens, Olivier Blin, Jill C. Richardson, Regis Bordet, Anders Wallin, Carl Eckerstrom, José Luis Molinuevo, Sebastiaan Engelborghs…

    Citation: Alzheimer's Research & Therapy 2018 10:100

    Published on:

  46. Content type: Correction

    Following publication of the original article [1], the author reported errors in the formatting of the table. The details of the errors are as follows:

    Authors: Susanne Ostrowitzki, Robert A. Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelkovic, Bruno Dubois, Mercè Boada, Kaj Blennow, Luca Santarelli…

    Citation: Alzheimer's Research & Therapy 2018 10:99

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2017 9:95

  47. Content type: Research

    Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by neuropathologic changes involving beta-amyloid (Aβ), tau, neuronal loss, and other associated biological events. While levels o...

    Authors: Umesh Gangishetti, J. Christina Howell, Richard J. Perrin, Natalia Louneva, Kelly D. Watts, Alexander Kollhoff, Murray Grossman, David A. Wolk, Leslie M. Shaw, John C. Morris, John Q. Trojanowski, Anne M. Fagan, Steven E. Arnold and William T. Hu

    Citation: Alzheimer's Research & Therapy 2018 10:98

    Published on:

  48. Content type: Research

    Age is the cardinal risk factor for Alzheimer’s disease (AD), and white matter hyperintensities (WMH), which are more prevalent with increasing age, may contribute to AD. Higher cardiorespiratory fitness (CRF)...

    Authors: Clayton J. Vesperman, Vincent Pozorski, Ryan J. Dougherty, Lena L. Law, Elizabeth Boots, Jennifer M. Oh, Catherine L. Gallagher, Cynthia M. Carlsson, Howard A. Rowley, Yue Ma, Barbara B. Bendlin, Sanjay Asthana, Mark A. Sager, Bruce P. Hermann, Sterling C. Johnson, Dane B. Cook…

    Citation: Alzheimer's Research & Therapy 2018 10:97

    Published on:

  49. Content type: Research

    We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patient...

    Authors: Stephen Salloway, Lee A. Honigberg, William Cho, Michael Ward, Michel Friesenhahn, Flavia Brunstein, Angelica Quartino, David Clayton, Deborah Mortensen, Tobias Bittner, Carole Ho, Christina Rabe, Stephen P. Schauer, Kristin R. Wildsmith, Reina N. Fuji, Shehnaaz Suliman…

    Citation: Alzheimer's Research & Therapy 2018 10:96

    Published on:

  50. Content type: Research

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a high prevalence among the elderly and a huge personal and societal impact. Recent epidemiological studies have indicated that the inc...

    Authors: Sylvie L. Lesuis, Lianne Hoeijmakers, Aniko Korosi, Susanne R. de Rooij, Dick F. Swaab, Helmut W. Kessels, Paul J. Lucassen and Harm J. Krugers

    Citation: Alzheimer's Research & Therapy 2018 10:95

    Published on:

Submit a manuscript

Follow

  • ISSN: 1758-9193

Advertisement

Alzheimer's Research & Therapy

ISSN: 1758-9193